| Title: | Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer |
|---|
| Authors: | ID Merlo, Sebastjan (Author)
ID Bešić, Nikola (Author)
ID Drmota, Eva (Author)
ID Kovačević, Nina (Author) |
|---|
| Files: |  PDF - Presentation file, download (299,16 KB)
MD5: 75DB188D6EF7432F0C9D2933A44F3FB3
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Background. Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is used as a prognostic marker and its level is elevated in more than 85% of women with advanced stages of epithelial ovarian cancer (EOC). The standard treatment is primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Several studies have been conducted to find out whether preoperative CA-125 serum levels influence treatment choice, surgical resection and survival outcome. The aim of our study was to analyse experience of single institution as Cancer comprehensive center with preoperative usefulness of CA-125. Patients and methods. At the Institute of Oncology Ljubljana a retrospective analysis of 253 women with stage FIGO IIIC and IV ovarian cancer was conducted. Women were divided into two groups based on their primary treatment. The first group was the NACT group (215 women) and the second the PDS group (38 women). The differences in patient characteristics were compared using the Chi-square test and ANOVA and the Kaplan-Meier method was used for calculating progression-free survival (PFS) and overall survival (OS). Results. The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively. The PFS in the NACT group was 8 months (95% CI 6.4%9.5) and 18 months (95% CI 12.5%23.4) in the PDS group. The median OS was lower in the NACT group than in the PDS group, 25 months (95% CI 20.6%29.5) and 46 months (95% CI 32.9%62.1), respectively. Conclusions. Preoperative CA-125 cut off value of 500 IU/ml is a promising threshold to predict a successful PDS. |
|---|
| Keywords: | ovarian cancer, tumour marker, neoadjuvant chemotherapy, CA-125 |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.09.2021 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2021 |
|---|
| Number of pages: | str. 341-346, X |
|---|
| Numbering: | Vol. 55, no. 3 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-19602  |
|---|
| UDC: | 618.1 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2021-0013 |
|---|
| COBISS.SI-ID: | 53289475 |
|---|
| Copyright: | by Authors |
|---|
| Publication date in DiRROS: | 22.07.2024 |
|---|
| Views: | 308 |
|---|
| Downloads: | 114 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
